Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Brightol
Suzhou, Jiangsu, Chinabrightol.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Brightol is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on high-prevalence diseases, particularly in the fields of metabolic disorders, oncology, and inflammatory diseases. Brightol leverages its proprietary drug discovery platform to develop next-generation treatments, including multi-target agonists for metabolic health. Its lead program, BRL-03, is an oral small molecule GLP-1 receptor agonist currently in Phase 1 clinical trials for the treatment of obesity and type 2 diabetes. The company aims to provide more convenient and accessible oral alternatives to existing injectable peptide therapies.
- Therapeutic areas
- OncologyEndocrinologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Brightol.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Brightol.